FACTSHEET • OCTOBER 2024




WS Amati Global Innovation Fund



Fund Objective

The Fund aims to provide capital growth and to outperform global equity markets over the medium to long term (3-5 year period), by investing in companies that create value from innovative products, services and business models that address key challenges facing businesses, consumers and societies, where the impact of such innovation is not fully priced by the market. The recommended holding period is 5 years or more. To read more, please go to: Fund Overview



Ratings, Awards & Signatories

Signatory of:

















Contact Details

Investment Manager

Amati Global Investors Ltd 8 Coates Crescent Edinburgh EH3 7AL

T: +44 (0) 131 503 9115 F: +44 (0) 131 503 9110

E:_info@amatiglobal.com

W:_www.amatiglobal.com

ACD of the Fund

Waystone Management 3rd Floor 29 Wellington Street Central Square Leeds, LS1 4DL

T: 0345 922 0044

E: wtas-investorservices @waystone.com

W: Waystone Manageme (UK) Limited

UK	
nt	
· · · · · ·	

Key Information

Available Platforms	Click here for list of available platforms
Launch Date	May 2022
	0.750/ 4

0.75% Annual Mgt Charge plus research charge of up to 0.10% (OCF capped at 1%) Charges (no initial)

Fund Size	£13.3m
Share price (B Class)	125.39p
Share price (C Class)	99.39p
ISAable fund	Yes
IA Sector	Global
No. of Holdings	40
Minimum Investment	£1,000
Net Dividend Yield	0.3%
Initial Charge	0%
Min Lump Sum Regular	£50/month
Share Type	B Accumulation
Scheme Type	UK UCITS
ISIN	GB00BKVF3N76
Benchmark	MSCI ACWI

PTC Inc
Novone
Bruker
Leonard
Samsun

10 Largest Holdings	% OF TOTAL ASSETS
PTC Inc	3.6%
Novonesis	3.6%
Bruker Corp	3.4%
Leonardo	3.4%
Samsung Electronic	3.4%
Autodesk Inc	3.3%
Danaher Corp	3.1%
Intuitive Surgi	3.0%
Wolters Kluwer	3.0%
Labcorp Holdings	2.9%

Cumulative Performance				(B CLASS)
	Fund Return* (%)	Benchmark Return** (%)	Avg Sector *** (%)	Q'tile Rank
1 month	0.58	1.99	1.17	3
3 months	-1.81	2.47	1.38	4
6 months	3.90	7.98	4.41	3
1 year	27.56	25.34	21.87	1
2 year	24.97	31.41	24.20	3
Since Launch#	25.39	34.30	26.31	3

Cumulative performance data as at 31/10/2024

Past performance is not a reliable indicator of future performance.

Discrete Annual Performance Fund Return (%) Benchmark Return (%) 31/10/2024 27.56 25.34 31/10/2023 4.85 -2.03


Investment Team






















Investment Report

October was a volatile month marked by the uncertainty of the upcoming US elections, with candidates often tied in the polls. While the market knew what to expect from a potential new Trump administration (as opposed to being taken by surprise the first time around in 2016), the candidate's policy implications for interest rates and inflation meant the stakes were high and the outcome unclear.

Core inflation in the US remained elevated, confounding expectations that the September interest rate cut would be followed by further robust rate reductions, and stalling the equity market rally that had been in place for much of the year. Beyond the financial markets, other sources of global uncertainty, such as the conflict in the Middle East and the war in Ukraine, maintained the broader geopolitical tension.

October is usually marked by the start of Q3 "results season" and so top contributors to, and detractors from, the fund performance in the month usually reflected a positive or negative result announcement

The top contributor overall was a recent addition to the portfolio, **Procept BioRobotics**, a manufacturer of robotic surgery systems for the treatment of benign prostate condition. Revenues grew strongly, reflecting both surgical volumes and a successful launch of the new model of their robot. The company has begun trialling its machines for prostate cancer treatment, which will significantly expand its addressable market if successful. We remain enthusiastic about the prospects for the business.

Another strong performer was **Leonardo DRS**, a long-held supplier of defence technology systems to US and other western armed forces. The company beat expectations and raised forecasts. In its key areas of innovation, from radars and sensors to anti-missile defence equipment to naval propulsion systems, DRS continues to win orders and grow its backlog.

In the same area of defence and intelligence technology, **Booz Allen Hamilton** also surprised positively and upped their growth guidance. The company's growth is tracking ahead of its own long term growth expectations and is hiring staff to satisfy the growing demand, but it has been a strong performer for the fund since launch and our investment case is increasingly well priced in by the consensus.

On the negative side, **Bruker**, a US listed supplier of analytical instruments to life science industry and academia, was weak on consistent commentary from its life sciences tools peers that, while the bottom in the demand cycle may have been reached, the pace of recovery remains uncertain. Key pockets of demand, including China and early-stage biotech, remain subdued. We see the long term case for the company as unchanged and continue to hold a large position size in the fund.

Edenred, a French listed provider of employee benefit programmes, continued to be pressured by the perceived risk of regulatory change in some of its European markets. We see these risks as priced in, with the market already assuming a worst case scenario in many areas. In the meantime, underlying growth in Edenred's business model is no longer factored in, with the shares having de-rated to a decade-low valuation rating. We retain our position.

We added two new holdings to the portfolio in October.

US listed **Allegro Microsystems** is a global leader in magnetic sensors. These highly specialist devices measure currents in electrical systems, from solar panel inverters to electric vehicle battery charging systems, and determine position, angle and speed in electro-mechanical systems, from robotic arms to auto steering columns. Its key end markets are auto and industrial, both undergoing a cyclical slow-down and inventory correction. However, these transitory headwinds obscure the underlying structural growth, creating an attractive entry point into this long-term opportunity.

French listed **VusionGroup** is a global leader in electronic shelf labels (ESLs). ESLs are small electronic screens replacing traditional printing labels, saving retailers cost and time to update their pricing and adding digital functionality that helps with re-stocking shelves and picking e-commerce orders in store. VusionGroup already supplies leading retailers, including Wal-Mart in the US, but the global adoption of ESLs is at a very early stage and we see a long runway for growth ahead.



To fund these new purchases we took profit in **Fabrinet**, the contract manufacturer of photonics systems. Fabrinet's shares rallied from their lows as the company delivered strong growth, including from supplying its services to NVidia. We feel that too much enthusiasm is now priced into the stock and our client's capital is better deployed elsewhere.

We also exited a position in **Ipsos**, a French marketing services provider. We thought that Ipsos' offering of focus groups and consumer panels, with increasingly sophisticated data and digital tools, will be resilient to the changes in digital advertising ecosystem and may benefit from more sophisticated data analytics techniques, including Al. However, the company consistently disappointed on its growth and our conviction in our original investment case had reduced. We no longer see it as a good use of our clients' capital and see better opportunities elsewhere.

At the time of writing we have definitive results of the US elections, which has already started to impact market sentiment and will continue to do so for a while as the incoming Trump administration's policies become clear. We expect the market to remain volatile, which to us presents an opportunity. Our 3-5 year time horizon gives us a luxury to look through the near term sentiment swings and continue to seek technologically inevitable structural changes and companies that benefit from those. At times of macro or political sentiment volatility such companies are often available at prices that do not fully reflect their long term value. We expect to be busy considering new opportunities for the portfolio in the months to come.





Risk Warning

Past performance is not a reliable guide to future performance. The value of investments and the income from them may go down as well as up and you may not get back the amount originally invested. Tax rates, as well as the treatment of OEICs, could change at any time. The return on investments in overseas markets may increase or decrease as a result of exchange rate movements. There may be occasions where there is an increased risk that a position in the Fund cannot be liquidated in a timely manner at a reasonable price. In extreme circumstances this may affect the ability of the Fund to meet redemption requests upon demand. A dilution levy may be applied to the share price when the fund is expanding or contracting. Should you buy or sell in these circumstances it may have an adverse impact on the return from your investment.

This factsheet does not provide you with all the facts you need to make an informed decision about investing in the Fund. Before investing you should read the Key Investor Information Document (KIID) and associated Fund documentation. If you are in any doubt as to how to proceed you should consult an authorised intermediary.

Fund documentation can be requested from Waystone Management (UK) Limited or Amati using the contact details above, and is available to download from our <u>website</u>.

Issued by Amati Global Investors Limited, which is authorised and regulated by the Financial Conduct Authority.